Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Recognised for the part he played in the discovery of anti-TNF therapy, Dr Feldmann is now exploring whether the antibody can be effective for COVID-19.

Sir Marc Feldmann, Emeritus Professor at the Kennedy Institute of Rheumatology, University of Oxford has been awarded the 2020 Tang Prize in Biopharmaceutical Science. He was announced as joint winner alongside Charles Dinarello (US), and Tadamitsu Kishimoto (Japan) "for the development of cytokine-targeting biological therapies for treatment of inflammatory diseases."

Dr Feldmann received the award for his research into the molecular mechanisms of auto-immune inflammatory diseases. This revealed that tumor necrosis factor (TNF), a protein which regulates immune and inflammatory cells was a good therapeutic target in rheumatoid arthritis. This discovery led to the development of an anti-TNF antibody that Feldmann, and his clinical research colleague Maini, proved to be very effective against rheumatoid arthritis and has since enabled millions of patients to regain control of their lives. Anti-TNF was also shown to be effective in inflammatory bowel disease, psoriasis and ten other conditions. It was the first antibody therapy of a common disease, is the world's best-selling drug class, and facilitated the widespread uptake of antibody therapy by the pharmaceutical industry.

"It is wonderful to receive a prestigious International award, such as the Tang Prize, as it recognizes the esteem of those best placed to judge, one's peers, of the impact of my work. Coming 20 years after the first prize I received, the Crafoord prize of the Royal Swedish Academy, is especially pleasing as it reflects the long lasting impact of anti-TNF therapy on medicine. It is a pleasure to share this prize with esteemed colleagues, Tadamitsu Kishimoto and Charles Dinarello, but I would like also to dedicate it to my long term partner in anti-TNF therapy Sir Ravinder Maini," said Dr Feldmann. "My current priority is working with colleagues in Oxford to evaluate whether anti-TNF will be an effective treatment for the hyperinflammation in COVID-19".

Established by Taiwanese entrepreneur Dr. Samuel Yin, the biannual Tang Prize awards up to three recipients in each of four categories. It aims to promote the interaction and cooperation between culture and technology so as to find a 21st century path to the sustainable development of the world.

Similar stories

Oxford-Bristol Myers Squibb Fellowships awarded to NDORMS researchers

Researchers from the Kennedy Institute of Rheumatology have been awarded fellowships as part of the Oxford-Bristol Myers Squibb Fellowship Programme. Among six researchers from across NDORMS, the programme provides them with an opportunity to gain exposure to the field of commercial drug discovery and development.

New Associate Professors announced at NDORMS

The Medical Sciences Division has awarded the title of Associate Professor to five senior researchers at NDORMS

Doctor Ghada Alsaleh awarded a Versus Arthritis Career Development Fellowship

Postdoctoral Researcher Ghada Alsaleh has been awarded a research grant by Versus Arthritis which she will use to develop a new therapy for osteoarthritis.

NDORMS researchers awarded ECTS prizes

Professor Anjali Kusumbe and Professor Cyrus Cooper have been presented with research awards by the European Calcified Tissue Society (ECTS).

Professor Katja Simon elected to the Academy of Medical Sciences

Professor of Immunology Katja Simon has been elected as a Fellow of the Academy of Medical Sciences.

Professor Michael Dustin elected to the National Academy of Sciences

Recognised for his outstanding contributions to the field of immunology, Michael becomes the fourth Kennedy professor to be elected to the Academy.